Ceroflo

About Ceroflo

Ceroflo Limited is a Galway, Ireland-based medical device company established in 2017, focusing on the treatment and prevention of stroke. The firm is developing a catheter-delivered neurovascular implant to address Intracranial Atherosclerotic Disease (ICAD), a condition involving plaque buildup in brain arteries, which is a significant cause of stroke. The business model centers on the development and eventual commercialization of its proprietary medical device, the SubMax Stent, targeting a critical unmet clinical need in the neurovascular market.

Ceroflo was assembled by a team with deep experience in the medical device industry, many of whom were instrumental in Neuravi, a successful venture acquired by Johnson & Johnson. The founders include Chairman Eamon Brady and Director John O'Dea, who bring their experience from Neuravi, alongside prominent stroke interventionists Professor Tommy Andersson, Dr. Leonard Yeo, and Dr. Paul Bhogal, who identified the need for a new technological solution. This blend of entrepreneurial and clinical expertise underpins the company's strategy. The management team includes CEO Chloe Brown, who has over 20 years of experience in neuro-intervention and vascular devices, and CTO Brendan Casey.

The company's core product is the SubMax Stent, engineered specifically for the unique challenges of treating ICAD. Unlike first-generation devices, the SubMax Stent is designed to gently restore blood flow to the brain while minimizing risks such as hemorrhage and stroke. Ceroflo is currently advancing the SubMax stent towards human clinical trials, a critical step for regulatory approval and market entry. The company has secured significant funding to support this, including a €3.4 million grant from the Disruptive Technologies Innovation Fund (DTIF) and a €6.4 million investment round to finance a first-in-human trial involving 30 patients. Its primary target markets are clinicians and hospitals that perform neuro-interventional procedures.